Rajesh Krishna 博士是 Certara 战略咨询部门的一体化药物开发高级总监。在加入 Certara 之前，Rajesh 曾就职于默克、赛诺菲（即原来的安万特）和百时美施贵宝 (Bristol-Myers Squibb)，从事转化和临床开发方面，拥有超过 20 年的制药行业经验。Rajesh has been involved in the development of a variety of therapeutic modalities (e.g., oral small molecules, long acting injectables and implants, biologics, and vaccines) and therapeutic areas (e.g., infectious diseases, immunology, oncology, neurosciences, cardiovascular and metabolic diseases). While at Merck, he also spent a year at the MSD Translational Medicine Research Center in Singapore, where he was the early clinical lead with a focus on digital medicine and regional tropical diseases.
Rajesh has contributed to the clinical pharmacology components of over 40 INDs; to the design, development, execution, and reporting of over 200 Phase 1/1b studies; and to the worldwide registration of 9 new molecular entities, spanning many therapeutic areas. Rajesh received his Ph.D. in pharmaceutical sciences from the University of British Columbia, Canada and a mid-career MBA from Warwick Business School, UK. He is an elected fellow of both the American Association of Pharmaceutical Scientists and the American College of Clinical Pharmacology. Rajesh is a member of the editorial boards of the Journal of Clinical Pharmacology and BMC Medicine, and has published over 80 peer-reviewed publications. He has edited or co-edited 4 books on new drug development and is an adjunct assistant professor of pharmacology and therapeutics at Thomas Jefferson University.